{'fraction_non_alphanumeric': 0.0335195530726257, 'fraction_numerical': 0.0111731843575419, 'mean_word_length': 5.345132743362832, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Research progress of hepatitis C in 2018].

Up to now, all major direct-acting antiviral agents (DAAs) have been approved, pan-genotypic regimens are recommended globally, simple monitoring strategy is recommended. In 2018, hepatitis C research focused more on accessibility, rather than new regimens. With the joint efforts of government and social groups, more infected people are getting affordable treatment. In addition approval of DAAs from global pharmaceuticals, a variety of DAAs have been on the clinical trial and approved in our country, and more options are/will be available with clinical trials progress. Management of infected fetus, children, and pregnant women will attract researchers' attention.